BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $16,560,000 | -4.9% | 3,372,674 | +1.4% | 2.76% | -8.9% |
| Q3 2017 | $17,421,000 | -6.0% | 3,324,705 | -0.3% | 3.03% | -22.4% |
| Q2 2017 | $18,537,000 | -36.2% | 3,333,958 | -3.6% | 3.91% | -48.9% |
| Q1 2017 | $29,048,000 | +12.5% | 3,458,120 | -15.2% | 7.65% | -21.3% |
| Q4 2016 | $25,819,000 | +39.2% | 4,078,895 | -3.0% | 9.72% | +73.4% |
| Q3 2016 | $18,542,000 | +191.9% | 4,204,579 | +88.0% | 5.60% | +158.1% |
| Q2 2016 | $6,353,000 | +13.7% | 2,237,066 | +13.3% | 2.17% | +7.1% |
| Q1 2016 | $5,586,000 | -73.1% | 1,973,932 | -1.8% | 2.03% | -70.4% |
| Q4 2015 | $20,748,000 | -19.7% | 2,010,501 | -9.9% | 6.85% | -14.6% |
| Q3 2015 | $25,833,000 | -23.5% | 2,230,206 | -1.4% | 8.03% | -18.3% |
| Q2 2015 | $33,762,000 | +65.3% | 2,261,361 | 0.0% | 9.83% | +6.6% |
| Q1 2015 | $20,420,000 | -25.7% | 2,261,361 | 0.0% | 9.22% | -9.4% |
| Q4 2014 | $27,498,000 | – | 2,261,361 | – | 10.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |